1. Get more info on this report!
Vaccines 2011: World Market Analysis, Key Players, and Critical
Trends in a Fast-Changing Industry
Kalorama Information
The high growth rates and successful launch of several products recently have kept
interest in the global vaccine market high. The global market for vaccines experienced
strong growth through 2010 and this is expected to continue through the forecast
period. Growth is being fueled by new product introductions and rising usage in all
regions.
Kalorama Information has been closely following vaccine markets and since 2003 has
instituted a yearly market research report schedule to keep up with fast-moving
developments. Our latest comprehensive update, Vaccines 2011: World Market
Analysis, Key Players, and Critical Trends in a Fast-Changing Industry, examines the
market for vaccines used in humans for various disease. This state-of-the-industry
report is a must-have for any executive who wants to stay on top of a rapidly changing
market and see what’s expected based on analysis of major company pipelines.
Trends are discussed in this report including the introduction of needle-free systems
and the production of vaccines, as well as product safety, supply shortages, and the use
of vaccines to prevent pandemics and address bioterrorism, and innovations in vaccine
delivery systems. News and reports of vaccine-related illness tend to exacerbate the
public’s fears and result in higher rates of non-immunization, and these are discussed in
this edition of the report.
The report covers only commercialized vaccines and developmental vaccines for
diseases that are already vaccine-preventable; it does not cover emerging vaccines for
diseases that are not currently vaccine-preventable.
Included in this report are current market size and forecast for the following vaccines:
Pediatric Vaccines:
Combinations
Hepatitis
HIB
MMR
Pneumococcal

2. Poliovirus
Varicella
Other Pediatric
Adult Vaccines:
Cervical Cancer
Hepatitis
Influenza
Pneumococcal
Travel; DT; Misc.
Important trends such as vaccine safety, vaccine shortages, preventing pandemics,
vaccines and bioterrorism, DNA vaccination, innovations in vaccine delivery systems
and innovations in vaccine Production are covered in the report.
Kalorama has expanded the global perspective of this report in this edition, including
estimates of vaccine sales (pediatric and adult segments) in the following regions:
U.S.
Rest of North Amer.
South America
Europe
Japan
India
China
Rest of World
In addition, the report profiles key competitors in the vaccine industry. Companies
profiled in the report include:
AlphaVax, Inc.
Bavarian Nordic A/S
Baxter Healthcare
Bharat Biotech
Celldex Therapeutics
Crucell / Johnson and Johnson
Emergent biosolutions
GlaxoSmithKline
Medimmune
Merck & Co. Inc
Nabi Biopharmaceuticals
Novartis
Pfizer
Sanofi Pasteur

3. Revenue estimates for each market segment represent global revenues and are
expressed in current dollars. Estimates are provided for the historic 2005 to 2009 period
and forecasts are provided through 2014. Historical information for this report was
gathered from a wide variety of published sources including company reports and
filings, government documents, legal filings, trade journals, newspapers and business
press, analysts’ reports and other sources. Interviews with company representatives
and other experts were conducted to capture the perspectives from industry
participants’ point of view and assess trends... these form the basis of the forecasting
and competitive analysis.
Additional Information
Continued Climb for Pharma Vaccine Revenues
In an industry facing patent expirations and layoffs, vaccine products continue to offer
good news, according to healthcare market research publisher Kalorama Information.
The world market for preventative vaccines totaled $25.3 billion in 2010, up from $22.1
billion in 2009, according to its annual report on the industry, Vaccines 2011: World
Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry. The
report notes that the worldwide vaccine market is predicted to increase at a compound
annual rate of 9.3% during the next five years, as new product introductions continue
and the products are sold to emerging markets.
"Vaccines are a priority at the major companies and there has been no let-up in the
business in the four years that we have been tracking it annually," said Bruce Carlson,
publisher of Kalorama Information. "We continue to see over nine percent growth in
sales, and in some emerging markets the rate of growth is even faster. There is also a
strong pipeline that should sustain growth as new products are launched."
The healthcare market research firm indicated that sales to Latin America, India and
China will grow at double-digit rates.
Vaccines are commonly segmented into two target markets, adult and pediatric.
According to Kalorama Information, the pediatric vaccine market is larger, accounting
for more than half of the total market. Pediatric vaccines are also growing at a faster
rate than adult vaccines and this is expected to continue over the next five years.
Pneumococcal and "combination" DTaP vaccines continue to drive growth in the
pediatric sector, while influenza and hepatitis vaccine products are driving sales in the
adult segment of the market.
The world vaccines market is dominated by five major competitors: Sanofi Pasteur,
GlaxoSmithKline, Merck & Co., Pfizer, and Novartis. Together, they held four-fifths of
the market in 2010. All but Pfizer and Merck posted strong double-digit growth in their
vaccine businesses. Sanofi Pasteur, a subsidiary of Sanofi Aventis, was the leading

4. manufacturer, according to Kalorama Information, with GlaxoSmithKline a close second.
The company's position was largely due to its influenza products, although its
polio/pertussis/Hib products also account for a significant portion of its vaccine sales.
More information is available from Kalorama Information's report, Vaccines 2011: World
Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry, including
market forecasts, company profiles, and trends in the industry.
More Drug Delivery Reports by Kalorama Information
Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for
Vaccine and Biologics by Kalorama Information
The line between drug delivery and drug substance will continue to become more
elusive in the near future as shown in the analysis in this ...
Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) by
Kalorama Information
Drug delivery is evolving at a rapid rate with new drug product formulations being
discovered frequently. Advanced drug delivery deals with developing solutions for new
...
The World Market for Diabetes Treatments by Kalorama Information
This Kalorama Information report , The World Market for Diabetes Treatments, provides
market estimates and forecasts for the world market for diabetes treatments. The ...
The World Anesthesia Drug Market by Kalorama Information
This Kalorama Information report - The World Anesthesia Drug Market - focuses on
three primary segments of anesthesia: General Anesthesia Local Anesthesia Adjunctive
...
Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems by
Kalorama Information
With pharmaceutical companies increasingly looking for ways to extend the revenue-
earning lifetime of their biggest products, drug delivery has become an important focus
of the ...
See all reports like this >>
More Global Drug Delivery Reports
Global Drug Eluting Stents Market 2010-2014 by Infiniti Research Limited
TechNavio analysts forecast that the Global Drug Eluting Stents market will reach $5.7
Billion in 2014. One of the key factors contributing to this market's ...
World Diabetes Drug Market 2011-2021 by Visiongain
Where will revenue growth occur in the diabetes treatment market? Our new report

5. shows you the potential that drug market offers from 2011 to 2021, ...
Global Injectable Drug Delivery Market (2010 - 2015) by MarketsandMarkets
KEY TAKE AWAYS To define and measure the Injectable drug delivery market and its
various sub-segments with respect to ...
Drug Delivery: Surveying the Global Competitive Landscape by Espicom Healthcare
Intelligence
This report details some of the most exciting technology out there and the companies
who are developing ...
Intranasal Drug Delivery by Global Industry Analysts
This report analyzes the US market for Intranasal Drug Delivery in US$ Million by the
following Therapeutic Areas: Allergic Infections, Analgesics, Osteoporosis, and
Vaccinations. Annual ...
TABLE OF CONTENTS
EXECUTIVE SUMMARY
THE GLOBAL VACCINES INDUSTRY
Scope and Methodology
Overview
Pediatric Preventative Vaccines
The Market
The Market
Total Market
Issues and Trends
CHAPTER TWO: INTRODUCTION TO VACCINES
A Brief History: The Development of Vaccines
The Immune Response
Mechanism of Action
Types of Vaccines
Attenuated (Weakened) Live Viruses
Killed (Inactivated) Viruses
Toxoid Vaccines
Genetically Engineered/Modified Vaccines
 Subunit Vaccines
 Conjugate Vaccines
 DNA Vaccination
Vaccine Approval Process

6. CHAPTER THREE: PEDIATRIC PREVENTIVE VACCINES
Introduction
Childhood Immunization in the United States
Childhood Immunization Rates
Challenges to the Vaccine Delivery System
The Effect of U.S. Healthcare Reform
Recommended Childhood Immunization Schedule
State Immunization Recommendations
United Nations Initiatives
Pediatric Vaccine Products
BCG
Diphtheria, Tetanus, Pertussis, Hepatitis B and Polio
 Diphtheria
 Pertussis
 Tetanus
 Hepatitis B
 Poliomyelitis
 Enterotoxigenic Escherichia coli
Haemophilus Influenzae Type B
Hepatitis A
Measles, Mumps and Rubella
 Measles
 Mumps
 Rubella
Meningococcal Disease
Parainfluenza Virus Type 3
Pneumococcal Conjugate
Rotavirus
Respiratory Syncytial Virus
Varicella
Pediatric Vaccines in Development
Cost of Vaccines in the United States
The World Market for Pediatric Preventive Vaccines
Total Market Size and Forecast
Hepatitis Vaccine Market
 Market Analysis
 Leading Products and Competitors
Haemophilus Influenzae Type B Vaccine Market
 Market Analysis
 Leading Products and Competitors
Measles, Mumps and Rubella Vaccines

 Market Analysis

7. Combination Vaccines Market
 Market Analysis
 Leading Products and Competitors
Pneumococcal Vaccine

 Leading Products and Competitors
Poliovirus Vaccine

 Market Analysis
 Leading Products and Competitors
Varicella Vaccines
 Market Analysis
 Leading Products and Competitors
Other Vaccines Market
 Market Analysis
 Leading Products and Competitors
CHAPTER FOUR: ADULT PREVENTIVE VACCINES
Introduction
Adult Vaccine-Preventable Diseases: Facts and Figures
Global Influenza Surveillance Program
U.S. Surveillance
Recommendations for Adult Immunizations
WHO International Health Regulations
Adult Vaccine Products
Allergies
Cervical Cancer
Cholera
Dengue Fever
Diphtheria-Tetanus
Hepatitis

 Hepatitis A
 Hepatitis B
Influenza
Japanese Encephalitis
Malaria
Pneumococcal Disease
Rabies
Shingles
Typhoid Fever
Yellow Fever
Adult Vaccines in Development

8. Total Market Size and Forecast
Cervical Cancer Market
Market Analysis
Leading Products and Competitors
Hepatitis Market
Market Analysis
Leading Products and Competitors
Influenza Vaccine Market
Market Analysis
Leading Products and Competitors
Market Analysis
Leading Products and Competitors
Travel, DT, and Miscellaneous Vaccine Market
Market Analysis
Leading Products and Competitors
CHAPTER FIVE: VACCINES MARKET SUMMARY
Trends Driving the Vaccines Market
Market Size and Forecast
Vaccine Sales by Region
Vaccine Market Competitors
Pediatric Vaccines
Major Manufacturers’ Market Share
Adult Vaccines
Major Manufacturers’ Market Share
CHAPTER SIX: ISSUES AND TRENDS
Vaccine Safety
Refusal to Immunize
Obesity
Post-Licensure Surveillance
 Vaccine Adverse Event Reporting System
 The Vaccine Safety Datalink Project
 Phase IV studies
The Vaccine Injury Compensation Program
 Countermeasures Injury Compensation Program
World Health Organization
Other Initiatives
The Future of Vaccine Safety
Vaccine Shortages
Preventing Shortages in the Developed Countries
 Financial incentives
 Equitable pricing

9.  Vaccine stockpiles
Preventing Shortages in Developing Nations

 Vaccine bonds
Preventing Pandemics
U.S. National Vaccine Plan
Vaccines and Bioterrorism
Overview
Project Bioshield Act
National Bio and Agro-Defense Facility
Vaccine Treatment and Evaluation Units
Anthrax
Smallpox
Tularemia
Viral Hemorrhagic Fevers
DTC Advertising of Vaccines
DNA Vaccination
Innovations in Vaccine Delivery Systems
Edible Vaccines
Mucosal Delivery
Intranasal Delivery
Vaccine Patches
Vaccine Chips
Innovations in Vaccine Production
Tobacco Plants
Insects
Nanoparticle Systems
Cloning
CHAPTER SEVEN: COMPANY PROFILES
AlphaVax, Inc.
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Bavarian Nordic A/S
History and Lines of Business
Strategic Alliances

10. Vaccine Products
Financial Information
Baxter Healthcare
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Bharat Biotech
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Celldex Therapeutics
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Crucell /Johnson & Johnson
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Emergent biosolutions
History and Lines of Business Strategic Acquisition and Alliance
Vaccine Products
Financial
GlaxoSmithKline
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Medimmune
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Merck & Co. Inc
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Nabi Biopharmaceuticals
History and Lines of Business Strategic Alliance
Vaccine Products
Financial Information
Novartis

11. History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Sanofi Pasteur
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
COMPANY DIRECTORY
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Figure 1-1: World Market for Pediatric Vaccines 2005-2014 Revenues
Figure 1-2: World Market for Adult Vaccines 2005-2014 Revenues
CHAPTER TWO: INTRODUCTION TO VACCINES
Table 2-1: Impact of Vaccines in the 20th Century Annual Morbidity in the 20th
Century vs 2010
Figure 2-1: Attenuated Virus Production
Table 2-2: Vaccine-Preventable Diseases, June 2011
Table 2-3: VAERS Table of Reportable Events Following Vaccination
CHAPTER THREE: PEDIATRIC PREVENTIVE VACCINES
Table 3-1: Global Immunization Rates by Vaccine Type (DPT3, BCG, HepB,
Yellow Fever, Tetanus, Hib, MCV, Polio) 2009
Table 3-2: Immunization Profile of the United States: Population by Age Group,
Number of Vaccine-Preventable Diseases Reported by Disease 1990 - 2009
Table 3-3: U.S. Recommended Immunization Schedule for Children Ages 0
Through 6 Years, 2011
Table 3-4: U.S. Recommended Immunization Schedule for Adolescents Ages 7
to 18 Years, 2011
Table 3-5: Selected Pediatric Vaccines in Development, June 2011
Table 3-6: World Market for Pediatric Vaccines, 2006-2015..
Figure 3-1: Market Share of Pediatric Vaccines by Type 2010
Figure 3-2: Market Share of Pediatric Vaccines, by Type 2015
Table 3-7: World Market for Pediatric Vaccines by Region (U.S., Rest of North
America, South America, EU, Japan, India, China, Rest of World) 2006-2015
Revenues

12. Table 3-8: World Pediatric Hepatitis Vaccine Market 2006-2015
Table 3-9: World Hib Vaccine Market, 2006-2015
Table 3-10: World MMR Vaccines Market 2006-2015
Table 3-11: World Combination Vaccines Market 2006-2015
Table 3-12: World Pediatric Pneumococcal Vaccine Market 2006-2015
Table 3-13: World Poliovirus Vaccine Market 2006-2015
Table 3-14: World Varicella Vaccine Market 2006-2015
Table 3-15: World Pediatric Other Vaccines Market 2006-2015
CHAPTER FOUR: ADULT PREVENTIVE VACCINES
Table 4-1: Universal Adult Immunization Schedule 2011
Table 4-2: Adult Immunization Schedule for Populations with Special Medical
Conditions, 2011
Table 4-3: Initiatives to Require HPV Vaccination by U.S. State, 2011
Table 4-4: WHO Pandemic Classification Schedule
Table 4-5: Selected Adult Preventive Vaccines in Development, 2011
Table 4-6: World Market for Adult Preventive Vaccines, 2006-2015
Figure 4-1: Market Share of Adult Vaccines, by Type, 2010
Figure 4-2: Market Share of Adult Vaccines, by Type, 2015
Table 4-7: World Market for Adult Vaccines by Region (U.S., Rest pf North
Amer., South America, EU, Japan, India, China, Rest of World) 2006-2015
Table 4-8: World Cervical CancerVaccine Market 2006-2015
Table 4-9: World Hepatitis Vaccine Market 2006-2015
World Influenza Vaccine Market 2006-2015
Table 4-11: 2010 Estimated Population by Region (Africa, Asia, Europe, N.
America, Oceania, South America) and Selected Age Group (in millions)
Table 4-12: World Pneumococcal Vaccine Market 2006-2015
World Travel; Diphtheria-Tetanus; Miscellaneous Vaccines Market 2006-2015
CHAPTER FIVE: VACCINES MARKET SUMMARY
Figure 5-1: Sales Growth of Vaccines vs. Pharmaceuticals 2006-2015
Figure 5-2: World Market for Vaccines by Type 2006-2015
Table 5-1: The World Vaccines Market by Vaccine Type 2006-2015
Figure 5-3: World Market for Vaccines Share by Type (Pediatric, Adult), 2006,
2010 and 2015
Table 5-2: The World Vaccines Market by Region (U.S, Rest of North Amer.,
South America, EU, Japan, India, China, ROW) 2006-2015 Revenues (in
millions)
Table 5-3: Major Manufacturers’ Shares of the World Vaccine Market, 2010
Figure 5-3: 2010 World Vaccines Market Share, by Leading Competitors
Table 5-4: Major Manufacturer’s Shares of the World Pediatric Vaccine Market
2010
Figure 5-5: Market Share of Pediatric Vaccines Market, 2010
Table 5-5: Major Manufacturer’s Shares of the World Adult Vaccine Market 2010

13. Figure 5-6: Market Share of Adult Vaccines Market 2010
CHAPTER SIX: ISSUES AND TRENDS
Table 7-1: Selected Companies/Laboratories Developing Biodefense Vaccines
Available immediately for Online Download at
http://www.marketresearch.com/product/display.asp?productid=6277155
US: 800.298.5699
UK +44.207.256.3920
Int'l: +1.240.747.3093
Fax: 240.747.3004